Zentalis Pharmaceuticals Inc
ZNTL
$2.22
Closing
▼-3.48%
1D
▼-26.73%
YTD
ZNTL
BBG00R2K8TG4
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$158.21M
Analysts' Rating
BUY
Price Target (Mean)
9.50
Total Analysts
11
P/E
Operating Margin
0.00%
Beta
1.80
Revenue Growth
0.00%
52 week high
$18.02
52 week low
$2.14
Div. Yield
%
EPS Growth
-54.84
Company Profile
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
